{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "be:PDGFR",
      "entity_text" : "PDGFR",
      "entity_type" : "family"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:644241",
      "entity_text" : "nilotinib",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "XREF_BIBR XREF_BIBR XREF_BIBR However, dasatinib, nilotinib, and ponatinib also inhibit PDGFR but increase the risk of arterial occlusive events.",
  "reading_complete" : "2020-08-02T14:12:08Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T14:10:16Z",
  "trigger" : "inhibit",
  "evidence" : [ "nilotinib, and ponatinib also inhibit PDGFR" ],
  "pmc_id" : "6524858",
  "score" : 0
}